Alentis Therapeutics Announces Presentations at AASLD The Liver Meeting® 2022 Post published:November 4, 2022 Continue ReadingAlentis Therapeutics Announces Presentations at AASLD The Liver Meeting® 2022
Article published in The Journal of Hepatology highlights potential of Claudin-1 as a novel target for the treatment of hepatocellular carcinoma Post published:November 2, 2022 Continue ReadingArticle published in The Journal of Hepatology highlights potential of Claudin-1 as a novel target for the treatment of hepatocellular carcinoma
Swiss Innovation Agency to Co-fund Research Collaboration to Accelerate Discovery of Biomarkers for Fibrosis Post published:September 27, 2022 Continue ReadingSwiss Innovation Agency to Co-fund Research Collaboration to Accelerate Discovery of Biomarkers for Fibrosis
Alentis Therapeutics starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis Post published:January 4, 2022 Continue ReadingAlentis Therapeutics starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis
Alentis Therapeutics announces Board appointments Post published:November 9, 2021 Continue ReadingAlentis Therapeutics announces Board appointments
New Head of Oncology for Alentis Post published:November 1, 2021 Continue ReadingNew Head of Oncology for Alentis
New Head of Fibrosis for Alentis Post published:October 19, 2021 Continue ReadingNew Head of Fibrosis for Alentis
Alentis to Present Data at the EASL International Liver Congress 2021 Post published:June 23, 2021 Continue ReadingAlentis to Present Data at the EASL International Liver Congress 2021
Alentis Therapeutics Raises USD 67 Million in Series B Financing Post published:June 15, 2021 Continue ReadingAlentis Therapeutics Raises USD 67 Million in Series B Financing
Alentis founder receives prestigious French Academy of Science award Post published:December 23, 2020 Continue ReadingAlentis founder receives prestigious French Academy of Science award